Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invion ( (AU:IVX) ) just unveiled an announcement.
Invion Limited announced positive findings from the Safety Review Committee regarding its Phase I/II non-melanoma skin cancer trial using INV043. The trial showed no adverse events and indicated a reduction in lesion size post-treatment, with patients experiencing no pain, a significant advantage over existing treatments. The trial also highlighted INV043’s potential as a diagnostic tool, with cancer cells fluorescing under violet light, aiding in more precise surgical interventions. These findings support the continuation of the trial and contribute to the upcoming anogenital cancer trial in collaboration with the Peter MacCallum Cancer Centre.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on developing innovative treatments for cancer. The company is known for its lead drug candidate, INV043, which is used in the treatment of non-melanoma skin cancer and other cancer types.
Average Trading Volume: 82,664
Technical Sentiment Signal: Sell
Current Market Cap: A$7.37M
See more data about IVX stock on TipRanks’ Stock Analysis page.